Apyx Medical Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
25.9%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$59.4Mnext fiscal year
FY EPS (est.)
-$0.27next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenue Quarterly12.5MTarget: 59000000 to 60000000
Surgical Aesthetics Segment Revenue Quarterly10.7MTarget: 54000000 to 55000000
OEM Segment Revenue Quarterly18M
Gross Margin Quarterly6,350.0%Target: 62% to 63%
Watch Items
- FDA 510(k) clearance for power liposuction capability on the AYON Body Contouring SystemTrigger: Regulatory approval received in Q2 2026Action: Monitor commercial launch and integration of power liposuction handpieces into the AYON platform to drive domestic sales.
- Compliance with Perceptive Credit Agreement covenantsTrigger: Minimum revenue and maximum operating expense thresholdsAction: Track quarterly revenue performance and ensure operating expenses remain below the $45 million annual cap.
- International market expansion, particularly in South Korea and ChinaTrigger: Sales of Apyx One Console and single-use handpiecesAction: Evaluate international revenue contribution (currently 35.1% of total sales in Q1 2026) to offset domestic seasonality.
Research as of 20 Jun 2026